Regeneron Pharmaceuticals Inc. (REGN) Receives Neutral Rating from Robert W. Baird
Robert W. Baird reiterated their neutral rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research note issued to investors on Tuesday. They currently have a $448.00 price target on the biopharmaceutical company’s stock.
REGN has been the subject of a number of other research reports. Cowen and Company reiterated a hold rating and set a $430.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 5th. Wells Fargo & Co. restated a hold rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 8th. Roth Capital restated a buy rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, September 23rd. Citigroup Inc. restated a buy rating and issued a $470.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 23rd. Finally, Vetr downgraded Regeneron Pharmaceuticals from a buy rating to a hold rating and set a $422.08 target price for the company. in a research report on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $480.09.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.70% during midday trading on Tuesday, hitting $399.99. 91,574 shares of the stock were exchanged. The stock’s 50-day moving average price is $403.67 and its 200-day moving average price is $391.72. The firm has a market capitalization of $41.85 billion, a price-to-earnings ratio of 62.40 and a beta of 1.31. Regeneron Pharmaceuticals has a 1-year low of $329.09 and a 1-year high of $592.59.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.65 by $0.17. The firm earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The company’s revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the company posted $2.89 EPS. On average, analysts forecast that Regeneron Pharmaceuticals will post $11.00 EPS for the current year.
In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the sale, the director now directly owns 15,125 shares in the company, valued at $6,428,125. The sale was disclosed in a document filed with the SEC, which is available at this link. 10.40% of the stock is owned by insiders.
Several large investors have recently modified their holdings of REGN. IFP Advisors Inc increased its stake in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares during the last quarter. Advisory Services Network LLC increased its stake in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 326 shares during the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $140,000. Brave Asset Management Inc acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $157,000. Finally, Bessemer Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 171 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.